新型口服抗凝药物与华法林治疗左心室血栓的对照研究
Comparative study of novel oral anticoagulants and warfarin in the treatment of left ventricular thrombosis
黄珍珍 1饶芳 1邓理湘 2许莉莉 2凌云龙 2庞暘 2徐烨 2陆荣荣 1周达新 2朱文青 2陈庆兴 3葛均波2
作者信息
- 1. 新疆维吾尔自治区喀什地区第二人民医院(新疆喀什,844000)
- 2. 复旦大学附属中山医院心内科上海市心血管病研究所 国家放射与治疗临床医学研究中心
- 3. 新疆维吾尔自治区喀什地区第二人民医院(新疆喀什,844000);复旦大学附属中山医院心内科上海市心血管病研究所 国家放射与治疗临床医学研究中心
- 折叠
摘要
目的:评价新型口服抗凝药物(NOAC)与华法林治疗左心室血栓(LVT)的有效性和安全性.方法:入选2018年-2021年心脏超声诊断LVT并接受6个月以上抗凝治疗,同时完成1次及以上心脏超声随访的患者311例,分为NOAC组(76例)及华法林组(235例).抗凝治疗6个月后随访LVT直径及主要不良心血管事件(MACE).结果:NOAC组的抗凝有效率明显高于华法林组(97.4％vs 90.2％,P=0.046).经(3.2±1.1)年的随访,两组MACE无差异.结论:NOAC对LVT的抗凝有效率高于华法林,安全性与之相当.
Abstract
Objective:To evaluate the efficacy and safety of novel oral anticoagulants(NOAC)and warfarin in the treatment of left ventricular thrombosis(LVT).Methods:A total of 311 patients diagnosed with LVT by ech-ocardiography from 2018 to 2021,received anticoagulation therapy for more than 6 months and completed follow-up.They were divided into NOAC group(76 cases)and warfarin group(235 cases).LVT diameter and major ad-verse cardiovascular events(MACE)were detected 6 months after anticoagulant therapy.Results:The anticoagu-lation effective rate of NOAC group was significantly higher than that of warfarin group(97.4％vs 90.2％,P=0.046).After(3.2±1.1)years of follow-up,there was no difference in MACE between the two groups.Conclu-sion:NOAC has a higher anticoagulant efficacy than warfarin in LVT with the same safety as warfarin.
关键词
左心室血栓/新型口服抗凝药/华法林/主要不良心血管事件Key words
left ventricular thrombus/novel oral anti-coagulant/warfarin/major adverse cardiovascular events引用本文复制引用
出版年
2024
NETL
NSTL
万方数据